

Office of the Chair - Week of June 6 - 10, 2011

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Mark your calendars for resident graduation on Friday, June 17, 2011. Details to follow.

Meetings

Thursday	06/09/11	8:00 a.m.	Call Center Meeting
			<u>Resident Lectures:</u>
		8:00 a.m.	PGY-1 – “Introduction to Psychopharmacology” Dr. Carlos Santana PGY-2 – “Geriatric Psychiatry – Depression in the Elderly” Dr. Jonathan Stewart PGY-3 – “Interpersonal Psychotherapy” Dr. Robert Fernandez CHILD – Language “Language Disorders” Dr. Brenda Curtwright
		9:00 a.m.	PGY-1 – “Clinical Neurosciences – Stress, Emotion, Brain and Memory” Dr. David Diamond PGY-2 – “Geriatric Psychiatry – Other Dementias” Dr. Jonathan Stewart PGY-3 – “Clinical Case Conference” Dr. Kailie Shaw and Beth Reese, LCSW PGY-4 – “Neurology Review” Dr. Gabriel de Erausquin CHILD – “Language” Dr. Brenda Curtwright
		10:00 a.m.	PGY-2 – “Introduction to Child and Adolescent – Pervasive Developmental Disorders” Dr. Sandra Stock PGY-3 – “Advanced Psychopharmacology” Thea Moore, Pharm D PGY-4 – “Neurology Review” Dr. Gabriel de Erausquin CHILD – “Language” Dr. Brenda Curtwright

11:00 a.m. Residents Meeting
12:00 noon Journal Club
12:00 noon NO GRAND ROUNDS
1:00 p.m. GERI – “ECT” Dr. Jonathan Stewart

Friday 06/10/11 No Medical Student Lectures

In The Know!

Congratulations to Jamie Fernandez, M.D. for being awarded a \$360,000 three-year grant from the James and Esther King Biomedical Research Program in the category of New Investigator Research. The King Program sponsors innovative research seeking new insights into the prevention, diagnosis, treatment, and/or cure of tobacco-related diseases. Dr. Fernandez' project is Neuroendocrine Disruption and Nicotine Preference in a Rat Model of Postpartum Depression.

Congratulations to Dr. William Upshaw for his new role as the Education Director at Tampa General Hospital. He is joining Dr. Deborah Sanchez and Dr. Dominique Thuriere in supporting and coordinating our resident education at each clinical site. Welcome to the Training Office!

Happy Birthday wishes to Alicia Hubbard/June 10th and Ruta Dimaite/June 12th

On June 10, 2011, from 7:00 – 10:00 p.m. The Carter-Jenkins Center will present: Reel to Real “La Vie en Rose (2007). Original title is “La mome.” The session will be directed by Frances Marton, MSW, Associate Director, The Carter-Jenkins Center.

Research Happenings!

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Abilify IM Depot Study

ENROLLMENT ENDING SOON

Participants in this study can now continue to receive open-label Aripiprazole IM Depot until it is FDA approved up to a maximum of 8 years. Our site can enroll up to 6 additional subjects in this study through January, 2011. Participants are started on oral Abilify – once tolerability is determined, the participant is switched to Aripiprazole IM Depot. Aripiprazole IM Depot is administered monthly. All study related medications, labs, ECGs and study visits are at no charge to participants throughout the duration of the extension study (remember up to 8 years or until drug is FDA approved). Principal Investigator – Carlos Santana, M.D.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as adjunctive therapy in patients with major depression associated with Bipolar I Disorder. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator - Carlos Santana, M.D.

NEW AUTISM STUDY

We are happy to announce USF Psychiatry's participation in a Phase 4, Safety and Efficacy study of Aripiprazole in the long-term maintenance treatment of children and adolescents 6-17 years of age with irritability associated with Autistic Disorder. The study is divided into three phases - a 7-42 day screening period, a 13-26 week single-blind phase, and a 16-week double-blind, placebo-controlled phase. Kids ages 6-17 with autism are eligible to screen for this study. Call 813-974-2832 for more information. Principal Investigator - Mike Bengtson, MD.

Schizophrenia PRIDE Study - Jail Recidivism

A 15-month open label study comparing oral antipsychotic treatment to paliperidone palmitate injections in delaying arrest recidivism in adults with Schizophrenia. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 90 days prior to screening. Subjects receive antipsychotic medications at no charge. Principal Investigator - Jean Fils, M.D.

<http://health.usf.edu/medicine/psychiatry/research/index.htm>